<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03556280</url>
  </required_header>
  <id_info>
    <org_study_id>CA-0005</org_study_id>
    <nct_id>NCT03556280</nct_id>
  </id_info>
  <brief_title>Multi-Center Study of Sensory Stimulation to Improve Brain Function</brief_title>
  <acronym>Overture</acronym>
  <official_title>Multi-Center Study of Sensory Stimulation to Improve Brain Function (Overture Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cognito Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cognito Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Overture Study is a randomized, controlled, single-blind multi-center clinical trial
      using the GammaSense Stimulation system to study safety, tolerability, and efficacy in people
      with mild to moderate cognitive impairment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Overture Study (CA-0005) is a Phase I/II randomized, controlled, single-blind
      multi-center clinical trial using the GammaSense Stimulation device to study safety,
      adherence rates and efficacy in subjects with mild to moderate cognitive impairment (MMSE
      14-26) who are age 55 and older.

      Subjects who pass screening will be randomized (ratio 2:1 Treatment to Control). Subjects and
      their caregivers will be blinded to their randomization group, as will key raters at each
      site. The device will be used for 60 minutes daily during the 6-month therapy phase, followed
      by a one month safety follow-up visit.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 24, 2018</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)</measure>
    <time_frame>Quarterly over 6 months</time_frame>
    <description>A widely accepted, validated measure of cognitive function in Alzheimer's Disease consisting of 14 questions that result in a score ranging from 0 to 90 with higher scores representing greater cognitive impairment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amyloid PET/CT</measure>
    <time_frame>Quarterly over 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Cognitive Impairment</condition>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Dementia Alzheimers</condition>
  <condition>Dementia, Mild</condition>
  <condition>Dementia, Alzheimer Type</condition>
  <condition>Dementia of Alzheimer Type</condition>
  <condition>Dementia</condition>
  <condition>Cognitive Impairment, Mild</condition>
  <condition>Cognitive Decline</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will use the Active GammaSense Stimulation System.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Will use the Sham GammaSense Stimulation System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GammaSense Stimulation System (Active Settings)</intervention_name>
    <description>Proprietary auditory and visual sensory stimulation device.</description>
    <arm_group_label>Treatment Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GammaSense Stimulation System (Sham Settings)</intervention_name>
    <description>Proprietary auditory and visual sensory stimulation device.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;= 55 Years old

          -  MMSE 14-26

          -  Prodromal Alzheimer's Disease (AD), AD or Mild Cognitive Impairment (MCI) due to AD

          -  Participation of a caregiver

        Exclusion Criteria:

          -  Profound hearing or visual impairment

          -  Seizure Disorder

          -  Use of memantine (Namenda or Namzaric)

          -  Implantable devices (non-MR compatible)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34994</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices &amp; Research, Inc</name>
      <address>
        <city>Methuen</city>
        <state>Massachusetts</state>
        <zip>01844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Center for Memory</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices &amp; Research, Inc</name>
      <address>
        <city>Portsmouth</city>
        <state>New Hampshire</state>
        <zip>02801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cognitive and Research Center of New Jersey</name>
      <address>
        <city>Springfield</city>
        <state>New Jersey</state>
        <zip>07081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>January 3, 2020</last_update_submitted>
  <last_update_submitted_qc>January 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dementia</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Cognitive Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

